Filtered By:
Drug: Docetaxel

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 178 results found since Jan 2013.

Decreased Expression of HN1 Sensitizes Prostate Cancer Cells to Apoptosis Induced by Docetaxel and 2-Methoxyestradiol
CONCLUSION: HN1 is an anti-apoptotic molecule and inhibits Docetaxel and 2-Methoxyestradiol induced apoptosis by targeting Cyclin B1.PMID:35414498
Source: Annals of Clinical and Laboratory Science - April 13, 2022 Category: Laboratory Medicine Authors: Lokman Varisli Source Type: research

Cancers, Vol. 14, Pages 1877: The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers
s Borhane Annabi Sortilin (SORT1) receptor-mediated endocytosis functions were exploited for this new approach for effective and safe treatments of gynecological cancers. Here, high expression of SORT1 was found in >75% of the clinically annotated ovarian and endometrial tumors analyzed by immunohistochemistry. Therefore, the anticancer properties of the peptide-drug conjugate TH1902, a peptide that targets SORT1 and which is linked to docetaxel molecules, were investigated both in vitro using ovarian and endometrial cancer cell cultures and in vivo using xenograft models. In vitro, TH1902 inhibited cell p...
Source: Cancers - April 8, 2022 Category: Cancer & Oncology Authors: Jean-Christophe Currie Michel Demeule Cyndia Charfi Alain Zgheib Alain Larocque Bogdan Alexandru Danalache Amira Ouanouki Richard B éliveau Christian Marsolais Borhane Annabi Tags: Article Source Type: research

Targeted Nanoparticle for Co ‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis (Small 11/2022)
Breast Cancer TreatmentIn article number2107550, Wassana Yantasee and co-workers develop polymer-decorated mesoporous silica nanoparticles for HER2-positive breast cancer treatment. This patented versatile platform can co-deliver multiple therapeutic classes to ensure that they reach the target cells at the same time to fully realize their synergy. Illustrated herein are nanoparticles with three drug cargos: HER2 antibody, HER2 siRNA, and chemotherapeutic docetaxel.
Source: Small - March 17, 2022 Category: Nanotechnology Authors: Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz ‐Muñoz, Moataz Reda, Husam Y. Zaidan, Natnaree Siriwon, Suphalak Marshall, Ruijie Wang, Molly A. Nelson, Justin P. C. Rehwaldt, Joe W. Gray, Kullervo Hynynen, Wassana Yantasee Tags: Cover Picture Source Type: research

Bone-targeted nanoplatform enables efficient modulation of bone tumor microenvironment for prostate cancer bone metastasis treatment
Drug Deliv. 2022 Dec;29(1):889-905. doi: 10.1080/10717544.2022.2050845.ABSTRACTAs there is currently no effective therapy for patients with prostate cancer (PCa) bone metastasis, it was stringent to explore the relevant treatment strategies. Actually, the interaction between cancer cells and bone microenvironment plays important role in prostate cancer bone metastasis, especially the Sonic hedgehog protein (SHH) signaling in the bone microenvironment. The SHH promotes osteoblast maturation and osteoblast then secretes RANKL to induce osteoclastogenesis. Herein, this study develops bone-targeting calcium phosphate lipid hyb...
Source: Drug Delivery - March 14, 2022 Category: Drugs & Pharmacology Authors: Xiangyu Zhang Qingbin Liu Tingting Zhang Pei Gao Hui Wang Lu Yao Jingwen Huang Shulong Jiang Source Type: research

Targeted Nanoparticle for Co ‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis
This research paper describes a new therapeutic candidate based on a nanoparticle that co-delivers siRNA against human epidermal growth factor receptor type 2 (HER2), trastuzumab, and docetaxel to treat advanced HER2+ breast cancer. The nanotherapeutic is more effective and safer than the free drug counterparts. It inhibits drug-resistant orthotopic and brain-metastatic HER2+ breast tumors in mice. AbstractThe first-line treatment of advanced and metastatic human epidermal growth factor receptor type 2 (HER2+) breast cancer requires two HER2-targeting antibodies (trastuzumab and pertuzumab) and a taxane (docetaxel or pacli...
Source: Small - January 27, 2022 Category: Nanotechnology Authors: Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz ‐Muñoz, Moataz Reda, Husam Y. Zaidan, Natnaree Siriwon, Suphalak Marshall, Ruijie Wang, Molly A. Nelson, Justin P. C. Rehwaldt, Joe W. Gray, Kullervo Hynynen, Wassana Yantasee Tags: Research Article Source Type: research

LncRNA LINC00184 promotes docetaxel resistance and immune escape via miR-105-5p/PD-L1 axis in prostate cancer
CONCLUSIONS: LINC00184 promoted docetaxel resistance and immune escape in prostate cancer cells by adsorption of miR-105-5p, resulted in upregulation of the expression of PD-L1. LINC00184 could possibly be considered as a potential target for treatment in prostate cancer patients with docetaxel-resistance.PMID:34896914 | DOI:10.1016/j.imbio.2021.152163
Source: Immunobiology - December 13, 2021 Category: Allergy & Immunology Authors: Wei Zhang Jun Xin Jinjin Lai Wenbin Zhang Source Type: research